Polycystic Kidney Disease Drugs Market Players:
- Otsuka Pharmaceutical Co., Ltd.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Exelixis, Inc.
- XORTX Therapeutics, Inc.
- AstraZeneca PLC
- Manros Therapeutics
- Regulus Therapeutics Inc.
- Reata Pharmaceuticals, Inc.
- Pano Therapeutics, Inc.
- Taro Pharmaceutical Industries Ltd.
- GlaxoSmithKline plc.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of polycystic kidney disease drugs is evaluated at USD 606.35 million.
The global polycystic kidney disease drugs market size was worth more than USD 571.38 million in 2025 and is poised to witness a CAGR of over 6.8%, crossing USD 1.1 billion revenue by 2035.
North America is projected to hold the majority revenue share by 2035 in the polycystic kidney disease drugs market, supported by rising per capita income and heightened awareness of early diagnosis.
Key players in the market include Otsuka Pharmaceutical Co., Ltd., Exelixis, Inc., XORTX Therapeutics, Inc., AstraZeneca PLC, Manros Therapeutics, Regulus Therapeutics Inc., Reata Pharmaceuticals, Inc., Pano Therapeutics, Inc., Taro Pharmaceutical Industries Ltd., GlaxoSmithKline plc.
